2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1332

Severe Complications and Immunosuppressive Treatments in 33 Patients with Relapsing Polychondritis
Abstract Number: 1333

Relevance of Granulomatous Presentation for the Diagnosis and Outcome of Uveitis: Retrospective Case-Control Study of 251 Patients
Abstract Number: 1334

Contribution of Diagnostic Investigations in the Management of Uveitis: Retrospective Analysis of 300 Patients
Abstract Number: 1335

Long–Term Safety and Efficacy of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis in an Ongoing Open-Label Study
Abstract Number: 1336

Tocilizumab for Uveitic Cystoid Macular Edema Refractory to Other Synthetic and Biological Immunosuppressive Drugs. Multicenter Study of 25 Patients
Abstract Number: 1337

Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
Abstract Number: 1338

Use of Subcutaneous Golimumab in Autoimmune Inner Ear Disease
Abstract Number: 1339

Rheumatic Immune Related Adverse Events of Checkpoint Therapy for Cancer: Case Series of a New Nosologic Entity
Abstract Number: 1340

Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution
Abstract Number: 1341

Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Literature Review
Abstract Number: 1342

Use of Immune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Diseases: A Systematic Review of Case Reports
Abstract Number: 1343

Efficacy of Biological-Targeted Treatments in MDS-Related Systemic Autoimmune Diseases: Multicenter Retrospective Study of 28 Patients
Abstract Number: 1344

Characteristics, Treatment and Outcome of Severe Pulmonary Hemorrhage Related to Systemic Disease: French Multicentric Study
Abstract Number: 1345

Undifferentiated Connective Tissue Disease: A 121 Patients Audit Focusing on Initial Diagnosis and Changes over Time
Abstract Number: 1346

Factors That Influence Therapy in Patients with Undifferentiated Connective Tissue Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].